학술논문
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer
Document Type
Article
Author
Source
In ESMO Open August 2022 7(4)
Subject
Language
ISSN
2059-7029